Online citations, reference lists, and bibliographies.
← Back to Search

Phase I/II RAF Kinase Inhibitors In Cancer Therapy

S. Turajlic, Z. Ali, N. Yousaf, James Larkin
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Introduction: Aberrant activation of RAF signalling is a frequent finding in human cancers. BRAF is the only RAF family member that is commonly mutated, whilst CRAF and ARAF play important roles in the signal transduction from mutant RAS. BRAF-specific inhibitors have been more effective in the treatment of BRAF-mutant melanoma than BRAF-mutant thyroid and colorectal cancers. Areas covered: The review summarises the experience with RAF kinase inhibitors, including efficacy, modes of acquired resistance, and the mechanism behind the progression of pre-malignant RAS-mutant lesions observed with RAF kinase inhibitors. The authors review all the completed and ongoing Phase I or II clinical trials of RAF kinase inhibitors and discuss in detail the rationale behind the combinatorial approaches. Expert opinion: The success of RAF kinase inhibitors has demonstrated the necessity of genotype-driven treatment selection for cancer patients. The spectrum of responses in different tumour types is explained by feedback events that are determined by cell lineage. Dissection of these events and the mechanisms of acquired resistance will determine the appropriate combination therapies. Ongoing characterisation of RAS-MAPK regulation in malignant cells may aid the development of novel agents that have greater potency for the inhibition of activated RAF kinase, and lesser propensity for promotion of RAS-mutant tumours.
This paper references
This paper describes the mechanism by which BRAF mutations activate the MAPK signalling pathway
10.1016/J.YPAT.2012.10.041
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
A. Mccullough (2013)
10.1158/1078-0432.CCR-11-2479
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
10.1016/j.cell.2009.12.040
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
10.1200/JCO.2011.29.15_SUPPL.8508
Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
W. Sharfman (2011)
10.1200/JCO.2008.20.3745
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).
G. Schwartz (2009)
10.1056/NEJMoa1014209
BRAF mutations in hairy-cell leukemia.
E. Tiacci (2011)
10.1200/JCO.2009.24.8252
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
S. Kopetz (2010)
10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
10.1038/nm0311-286
Targeting RAF: trials and tribulations
J. Downward (2011)
10.3816/CGC.2009.n.003
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Z. Dubauskas (2009)
10.1200/jco.2009.27.15_suppl.9000
Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.
K. Flaherty (2009)
10.1158/0008-5472.CAN-11-2941
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
H. Yang (2012)
10.1038/nature09882
DHODH modulates transcriptional elongation in the neural crest and melanoma
Richard M. White (2011)
10.1038/nature00766
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
10.1038/nature09837
Initial genome sequencing and analysis of multiple myeloma
M. A. Chapman (2011)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1038/sj.bjc.6603291
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen (2006)
10.1038/nrd2130
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm (2006)
10.1158/2159-8290.CD-12-0531
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
Cristina Montero-Conde (2013)
10.1038/nature10868
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
A. Prahallad (2012)
10.1016/S0092-8674(04)00215-6
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
P. Wan (2004)
10.1186/1479-5876-10-169
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
E. Ellebaek (2012)
10.1200/JCO.2010.28.15_SUPPL.3534
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
S. Kopetz (2010)
10.1200/JCO.2012.41.6750
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
Renal cell carcinoma and the use of sorafenib
James M G Larkin (2006)
10.1158/1535-7163.MCT-09-1014
Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
P. Mordant (2010)
10.1200/JCO.2009.23.4823
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
J. P. Arnault (2009)
10.1038/onc.2010.270
RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma
Y. Zhang (2010)
PLX4032 in metastatic colorectal cancer patients with BRAF tumors
S Kopetz (2010)
10.1038/nature10662
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
10.1158/1078-0432.CCR-11-2612
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
K. Paraiso (2012)
10.1200/JCO.2007.15.7636
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
BRAF inhibition can induce noncutaneous RAS-mutant cancers
(2013)
10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
10.1200/JCO.2008.18.2717
Phase II trial of sorafenib in metastatic thyroid cancer.
R. T. Kloos (2009)
10.1016/j.bcp.2010.04.029
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
Gajanan S. Inamdar (2010)
10.1016/j.mayocp.2012.07.006
Melanoma brain metastases and vemurafenib: need for further investigation.
N. Rochet (2012)
10.1158/2159-8290.CD-11-0341
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
R. Corcoran (2012)
10.1016/j.ccr.2011.04.002
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Rafael B Blasco (2011)
10.1158/1078-0432.CCR-11-1122
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Y. Su (2012)
10.1016/S0304-419X(03)00016-7
Raf proteins and cancer: B-Raf is identified as a mutational target.
K. Mercer (2003)
10.1158/1078-0432.CCR-11-0933
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
N. Jin (2011)
10.1158/0008-5472.CAN-05-1683
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Victoria Emuss (2005)
10.1200/JCO.2012.42.1677
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
M. Martin (2012)
10.1093/emboj/18.8.2137
Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation
C. Mason (1999)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.3410/f.6899956.7634054
Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
J. Chernoff (2011)
10.1200/JCO.2012.30.15_SUPPL.8510
Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.
J. Weber (2012)
This was the first paper to describe mutations in BRAF in cancer
10.1128/MCB.26.6.2262-2272.2006
Regulation and Role of Raf-1/B-Raf Heterodimerization
L. Rushworth (2006)
10.1158/2159-8290.CD-10-0044
C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
F. Karreth (2011)
10.1056/NEJMoa1112302
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
J. Sosman (2012)
10.1038/nature08658
A comprehensive catalogue of somatic mutations from a human cancer genome
E. Pleasance (2010)
10.1200/JCO.2011.36.7680
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
P. Oberholzer (2012)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1016/j.ccr.2010.11.023
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
10.1073/pnas.0711741105
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
J. Tsai (2008)
10.1038/nature08833
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
10.1016/S0898-6568(02)00139-0
Mechanisms of regulating the Raf kinase family.
H. Chong (2003)
10.1056/NEJMoa1210093
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
10.1200/jco.2009.27.15_suppl.3513
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.
G. Schwartz (2009)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1038/onc.2012.330
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
A. Rebocho (2013)
10.1158/0008-5472.CAN-10-0118
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and Phase I/II RAF kinase inhibitors in cancer therapy
A Hauschild (2013)
10.1038/ncomms1727
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
10.1158/1538-7445.AM2012-3790
Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
D. Stuart (2012)
10.1016/S0140-6736(12)60868-X
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A. Hauschild (2012)
10.1056/NEJMc081780
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar